Rafael Bejar

List of Publications by Year
in descending order

71 papers	9,022 citations	147801 31 h-index	110387 64 g-index
76 all docs	76 docs citations	76 times ranked	8677 citing authors

#	Article	IF	Citations
1	Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood, 2015, 126, 9-16.	1.4	1,493
2	Clinical Effect of Point Mutations in Myelodysplastic Syndromes. New England Journal of Medicine, 2011, 364, 2496-2506.	27.0	1,444
3	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/DendriticÂNeoplasms. Leukemia, 2022, 36, 1703-1719.	7.2	1,211
4	TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood, 2014, 124, 2705-2712.	1.4	486
5	Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 2012, 30, 3376-3382.	1.6	419
6	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	30.7	372
7	Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2014, 32, 2691-2698.	1.6	359
8	Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes. Journal of Clinical Oncology, 2011, 29, 504-515.	1.6	288
9	MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood, 2015, 126, 2355-2361.	1.4	280
10	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
11	Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 60-87.	4.9	254
12	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia, 2019, 33, 1747-1758.	7.2	195
13	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood, 2020, 136, 157-170.	1.4	195
14	Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS. Cancer Cell, 2014, 26, 509-520.	16.8	158
15	Recent developments in myelodysplastic syndromes. Blood, 2014, 124, 2793-2803.	1.4	147
16	Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia. Cancer Discovery, 2019, 9, 1080-1101.	9.4	119
17	Precancer Atlas to Drive Precision Prevention Trials. Cancer Research, 2017, 77, 1510-1541.	0.9	116
18	Transgenic Calmodulin-Dependent Protein Kinase II Activation: Dose-Dependent Effects on Synaptic Plasticity, Learning, and Memory. Journal of Neuroscience, 2002, 22, 5719-5726.	3.6	92

#	Article	IF	Citations
19	Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica, 2014, 99, 956-964.	3.5	91
20	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood, 2015, 126, 907-907.	1.4	85
21	The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine. Journal of Molecular Biology, 2018, 430, 2875-2899.	4.2	72
22	Managing Clonal Hematopoiesis in Patients With Solid Tumors. Journal of Clinical Oncology, 2019, 37, 7-11.	1.6	60
23	MDS overlap disorders and diagnostic boundaries. Blood, 2019, 133, 1086-1095.	1.4	58
24	Leveraging premalignant biology for immune-based cancer prevention. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10750-10758.	7.1	57
25	Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. Cancers, 2019, 11, 11.	3.7	46
26	Splicing Factor Mutations in Cancer. Advances in Experimental Medicine and Biology, 2016, 907, 215-228.	1.6	45
27	Implications of molecular genetic diversity in myelodysplastic syndromes. Current Opinion in Hematology, 2017, 24, 73-78.	2.5	44
28	X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation. Journal of Clinical Investigation, 2015, 125, 1665-1669.	8.2	43
29	Myelodysplastic Syndromes, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 261-272.	4.9	40
30	Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators. Rna, 2016, 22, 1535-1549.	3.5	40
31	Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling. Haematologica, 2019, 104, e388-e392.	3.5	40
32	Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?. Current Hematologic Malignancy Reports, 2015, 10, 282-291.	2.3	35
33	DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes. Blood Advances, 2019, 3, 2845-2858.	5.2	32
34	The Genetic Basis of Myelodysplastic Syndromes. Hematology/Oncology Clinics of North America, 2010, 24, 295-315.	2.2	28
35	Prognostic models in myelodysplastic syndromes. Hematology American Society of Hematology Education Program, 2013, 2013, 504-510.	2.5	28
36	Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS. Current Hematologic Malignancy Reports, 2017, 12, 461-467.	2.3	25

#	Article	IF	Citations
37	Clonal hematopoiesis in cancer. Experimental Hematology, 2020, 83, 105-112.	0.4	24
38	What biologic factors predict for transformation to AML?. Best Practice and Research in Clinical Haematology, 2018, 31, 341-345.	1.7	22
39	The effect of autonomous alpha-CaMKII expression on sensory responses and experience-dependent plasticity in mouse barrel cortex. Neuropharmacology, 2001, 41, 771-778.	4.1	20
40	Clonal Hematopoiesis in Aging. Current Stem Cell Reports, 2018, 4, 209-219.	1.6	18
41	Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation. Blood, 2019, 134, 1730-1744.	1.4	17
42	Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients. Leukemia Research, 2017, 52, 1-7.	0.8	14
43	What lies beyond del(5q) in myelodysplastic syndrome?. Haematologica, 2013, 98, 1819-1821.	3.5	13
44	Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. BMC Cancer, 2016, 16, 652.	2.6	12
45	Myelodysplastic Syndromes: Recent Advancements in Risk Stratification and Unmet Therapeutic Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e256-e270.	3.8	12
46	The importance of subclonal genetic events in MDS. Blood, 2013, 122, 3550-3551.	1.4	11
47	DMSO Increases Mutation Scanning Detection Sensitivity of High-Resolution Melting in Clinical Samples. Clinical Chemistry, 2015, 61, 1354-1362.	3.2	9
48	New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 480-494.	3.8	9
49	SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 613-620.	0.4	8
50	In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden. Cytotherapy, 2021, 23, 320-328.	0.7	8
51	New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 480-494.	3.8	8
52	The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes and Related Disorders. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 131-135.	4.9	7
53	Adoptive transfer of neoantigen-specific T-cell therapy is feasible in older patients with higher-risk myelodysplastic syndrome. Cytotherapy, 2021, 23, 236-241.	0.7	7
54	Somatic Mutations Indicative of Clonal Hematopoiesis Are Present in a Large Fraction of Cytopenic Patients Who Lack Diagnostic Evidence of MDS. Blood, 2014, 124, 3272-3272.	1.4	7

#	Article	IF	Citations
55	TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee. Blood, 2014, 124, 532-532.	1.4	6
56	<scp>JAK</scp>2 double minutes with resultant simultaneous amplification of <scp>JAK</scp>2 and <scp>CD</scp>274 in a therapyâ€related myelodysplastic syndrome evolving into an acute myeloid leukaemia. British Journal of Haematology, 2019, 185, 566-570.	2.5	5
57	Validation of a Prognostic Model and the Impact of SF3B1, DNMT3A, and Other Mutations in 289 Genetically Characterized Lower Risk MDS Patient Samples. Blood, 2011, 118, 969-969.	1.4	5
58	Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. Leukemia and Lymphoma, 2020, 61, 1455-1464.	1.3	4
59	5-Azacytidine Transiently Restores Dysregulated Erythroid Differentiation Gene Expression in TET2-Deficient Erythroleukemia Cells. Molecular Cancer Research, 2021, 19, 451-464.	3.4	3
60	Indolent Tâ€cell prolymphocytic leukemia with no expression of surface Tâ€cell receptors or surface CD3. International Journal of Laboratory Hematology, 2021, 43, O224-O226.	1.3	3
61	Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation. Blood, 2012, 120, 311-311.	1.4	3
62	Myelodysplastic Syndromes: Recent Advancements in Risk Stratification and Unmet Therapeutic Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e256-e270.	3.8	2
63	DNA Methylation Analysis before and during Treatment with Azacitidine Plus Pevonedistat or Azacitidine Alone in Patients with MDS, CMML, and AML Previously Untreated with Hypomethylating Agents. Blood, 2020, 136, 29-30.	1.4	1
64	Myelodysplasia. , 0, , 156-166.		0
65	How do molecular aberrations guide therapy in MDS?. Best Practice and Research in Clinical Haematology, 2021, 34, 101324.	1.7	0
66	Point Mutations In Myelodysplastic Syndromes Are Associated with Clinical Features and Are Independent Predictors of Overall Survival. Blood, 2010, 116, 300-300.	1.4	0
67	MYBL2 Is a Candidate Tumor Suppressor Gene In MDS. Blood, 2010, 116, 1865-1865.	1.4	0
68	Board Practice 1. , 2012, , 1062-1074.		0
69	Next generation sequencing to reveal potentially actionable alterations in the majority of patients with hematologic malignancies.. Journal of Clinical Oncology, 2017, 35, e23133-e23133.	1.6	0
70	Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematological Oncology, 2022, 40, 491-504.	1.7	0
71	Improving Patient Understanding and Outcomes in Myelodysplastic Syndromes - An Animated Patient Guide to MDS with Visual Formats of Learning.. Leukemia Research Reports, 2022, , 100328.	0.4	0